Thanks for these, both excellent reads and common sense that...

Thanks for these, both excellent reads and common sense that validated my own thinking and given me even more confidence and conviction.
Nobody is going to make a decent buck guessing where this stock will go over the next few weeks or months. I personally think what has happened recently is something strategic by big players, either a shift in their direction and timelines, or something a little shifty regarding price control. These are only my thoughts and musings of course.

Thanks again, I really resonated with their summaries

From BP
CONCLUSION Based on our first review of the data it does not appear unreasonable to assume a link between the favourable changes in radiographic evidence, favourable changes in biomarkers and the clinical outcomes achieved by participants in the trial. The clinical data continues to be highly supportive of the company’s ongoing efforts in the clinic as well as potential development partners.

From Lodge
Recommendation
While the data was promising in showing a consistent trend and further empirical evidence (via the MRI
images) it fell short in showing a definitive disease modifying result. However, the study was mainly
exploratory to see signals or signs of disease modifying. A larger study will be needed to prove DMOAD. As
detailed in the key points the varying reactions between the single and double dose arms as well as the varying
statistical p-values fell short of a definitive effect. However, the data set is only at the halfway point and the
full 12-month data set could be more definitive. The trial endpoints, which were change in pain from baseline
at day 56 and change in at least one biomarker, were achieved. As such we retain our $3.19 target however
we probably wont be certain of DMOAD until the results are published and peer reviewed on the full 12 month
data set for PARA_OA_008 which we anticipate will be due sometime between September and November of
2023.